Hospital
Mcsa LLC
Mcsa LLC was paid $4.31M by Medicaid between Jan 2018 and Jun 2023, across 175 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 8.9% of everything it billed.
33Billing provider infoMCSA LLC
EL DORADO, AR 71730
EL DORADO, AR 71730
33aNPI1689625568assigned 05/15/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.31M
24GClaims260,442
24DCodes billed175
24AFirst – last monthJan 2018 – Jun 2023
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#18 of 49
Median peer was paid$2.62M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,845 | $675K | |
| 2019 | 50,951 | $780K | |
| 2020 | 40,912 | $687K | |
| 2021 | 45,999 | $792K | |
| 2022 | 49,627 | $920K | |
| 2023 | 26,108 | $456K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 8.9% | 18,576 | 15,106 | $383K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 6.7% | 2,960 | 1,275 | $291K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.6% | 3,174 | 2,712 | $242K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.8% | 1,897 | 1,617 | $206K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.7% | 3,772 | 3,068 | $202K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 4.4% | 5,952 | 5,096 | $188K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.0% | 5,824 | 1,496 | $172K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.8% | 1,463 | 1,327 | $163K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 3.3% | 862 | 673 | $143K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.7% | 7,293 | 5,785 | $117K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.6% | 20,696 | 16,225 | $111K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 2.5% | 524 | 408 | $109K |
163 more codes
| 99283 | Emergency room visit (moderate) | 2.2% | 3,125 | $93K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 1,489 | $84K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 1,675 | $77K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.7% | 5,398 | $74K |
| 99284 | Emergency room visit (serious) | 1.5% | 3,537 | $63K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 9,152 | $60K |
| 87428 | 1.3% | 920 | $57K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1.3% | 2,877 | $56K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.2% | 571 | $54K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 7,238 | $49K |
| 81001 | 1.1% | 13,203 | $47K | |
| 84484 | 1.1% | 6,159 | $47K | |
| 80050 | General health panel | 1.1% | 976 | $46K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.0% | 1,107 | $45K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,795 | $43K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 291 | $41K |
| 80061 | Lipid panel | <1% | 4,338 | $38K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,280 | $35K |
| 87430 | <1% | 3,117 | $34K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,905 | $32K |
| 83880 | <1% | 2,103 | $31K | |
| 85027 | <1% | 5,004 | $31K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,714 | $29K |
| 81025 | <1% | 4,005 | $28K | |
| 99285 | Emergency room visit (most serious) | <1% | 2,411 | $28K |
| 87070 | <1% | 1,023 | $27K | |
| 97161 | <1% | 512 | $27K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,627 | $26K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 799 | $24K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,255 | $24K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,141 | $23K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,149 | $22K |
| 87186 | <1% | 2,021 | $22K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,258 | $22K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 511 | $21K |
| 82962 | <1% | 4,285 | $20K | |
| 82553 | <1% | 3,128 | $20K | |
| 86403 | <1% | 1,530 | $20K | |
| 86901 | <1% | 1,137 | $18K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,033 | $17K |
| 74018 | <1% | 902 | $17K | |
| 83735 | <1% | 4,078 | $17K | |
| 83690 | <1% | 3,248 | $16K | |
| 11043 | <1% | 114 | $15K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 200 | $15K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,255 | $15K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 914 | $14K |
| 87077 | <1% | 2,158 | $13K | |
| 83655 | <1% | 866 | $13K | |
| 82550 | <1% | 3,398 | $12K | |
| 87040 | <1% | 1,681 | $12K | |
| 84703 | <1% | 1,165 | $11K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 91 | $10K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,483 | $10K |
| 85610 | <1% | 2,414 | $8K | |
| 86850 | <1% | 747 | $8K | |
| 73221 | <1% | 46 | $8K | |
| 82150 | <1% | 1,733 | $8K | |
| 85730 | <1% | 1,602 | $8K | |
| 83874 | <1% | 1,155 | $8K | |
| 84439 | <1% | 1,355 | $8K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 199 | $7K |
| 88304 | <1% | 260 | $7K | |
| 73630 | <1% | 327 | $7K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 260 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 177 | $7K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 40 | $6K |
| 73610 | <1% | 332 | $6K | |
| 73030 | <1% | 290 | $6K | |
| 72141 | <1% | 31 | $6K | |
| 83605 | <1% | 790 | $6K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 494 | $5K |
| 93458 | <1% | 54 | $5K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 113 | $5K |
| 82805 | <1% | 242 | $5K | |
| 71020 | <1% | 377 | $5K | |
| 73560 | <1% | 274 | $5K | |
| 93017 | <1% | 406 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 36 | $4K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,065 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 978 | $4K |
| 85379 | <1% | 562 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 392 | $4K |
| 36416 | <1% | 213 | $4K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 16 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 89 | $3K |
| 97597 | <1% | 412 | $3K | |
| 81003 | <1% | 1,871 | $3K | |
| 73130 | <1% | 120 | $3K | |
| 59025 | Fetal non-stress test | <1% | 20 | $3K |
| 71010 | <1% | 482 | $3K | |
| 86900 | <1% | 1,125 | $3K | |
| 82607 | <1% | 261 | $3K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 39 | $2K |
| 87205 | <1% | 1,056 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 134 | $2K |
| 70486 | <1% | 14 | $1K | |
| 97001 | <1% | 30 | $1K | |
| 84702 | <1% | 123 | $1K | |
| 72100 | <1% | 63 | $1K | |
| 74022 | <1% | 54 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 682 | $955.84 |
| 82803 | <1% | 66 | $900.53 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 345 | $887.51 |
| 73110 | <1% | 48 | $883.70 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 45 | $830.02 |
| 80074 | <1% | 75 | $811.64 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,326 | $775.31 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,275 | $774.57 |
| 36430 | <1% | 15 | $750.00 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 706 | $711.53 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,796 | $646.37 |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 16 | $644.48 |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 12 | $619.20 |
| 74010 | <1% | 28 | $611.57 | |
| 73502 | <1% | 31 | $592.78 | |
| 76801 | <1% | 17 | $586.59 | |
| 76775 | <1% | 49 | $565.17 | |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $553.33 |
| 90715 | <1% | 42 | $460.80 | |
| 86922 | <1% | 31 | $454.96 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 19 | $452.40 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 757 | $436.44 |
| 76642 | <1% | 16 | $399.71 | |
| 85652 | <1% | 212 | $381.30 | |
| 93971 | <1% | 15 | $375.96 | |
| 86920 | <1% | 40 | $340.00 | |
| 84520 | <1% | 16 | $338.80 | |
| 73120 | <1% | 13 | $320.16 | |
| 85018 | <1% | 153 | $318.95 | |
| 71250 | <1% | 12 | $309.94 | |
| 83540 | <1% | 54 | $265.68 | |
| 82274 | <1% | 31 | $242.44 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,093 | $236.22 |
| 85576 | <1% | 15 | $214.76 | |
| 85014 | <1% | 78 | $202.80 | |
| 86592 | <1% | 26 | $196.20 | |
| 73070 | <1% | 14 | $180.00 | |
| 74000 | <1% | 13 | $180.00 | |
| 94760 | <1% | 26 | $168.00 | |
| 71015 | <1% | 12 | $154.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 223 | $137.81 |
| 82565 | <1% | 18 | $131.76 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 161 | $128.85 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 605 | $121.43 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 342 | $121.42 |
| 85007 | <1% | 36 | $108.24 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 33 | $107.93 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 265 | $100.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,653 | $54.16 |
| 84436 | <1% | 13 | $44.50 | |
| 86140 | <1% | 14 | $44.34 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 32 | $39.42 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 230 | $35.08 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 78 | $21.29 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 53 | $14.37 |
| J2704 | Injection, propofol, 10 mg | <1% | 283 | $13.56 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 843 | $1.15 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 46 | $0.00 |
| 99152 | 0% | 17 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 15 | $0.00 |
| P9016 | Red blood cells, leukocytes reduced, each unit | 0% | 15 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Northwest Hospital LLC | Tucson, AZ | $47.81M |
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.